Discovery and Development of Antibody Therapies for COVID-19
Neutralizing antibodies (nAbs) against SARS-CoV-2 represent a promising option for treating COVID-19. Screening a large and diverse antibody phage library has allowed for the rapid discovery of anti-SARS-CoV-2 nAbs.
In this expert webinar, find out how high-throughput epitope binning and mapping using label-free biolayer interferometry (BLI) detection and advanced flow cytometry systems has enabled the development of an antibody cocktail that can reduce the risk of drug resistance.
Download the webinar to learn more.